Group number |
allergen used in PCBAT |
Study group description |
n |
Age (years, Mean, ±SD) |
gender (% male) |
sIgE (KU/L, Mean, ±SD) |
n |
Age (years, Mean, ±SD) |
gender (% male) |
sIgE (KU/L) |
1 |
Cat |
Sensitised to cat |
18* |
41.2 (15.2) |
72.2% |
12.10 (24.52) |
6* |
61.0 (21.3) |
33.3% |
<0.4 |
2 |
Cat |
Asthma, on Omalizumab, sensitised to inhalant allergens |
4* |
45.9 (14.7) |
100% |
36.05 (47.52) |
N/A |
N/A |
N/A |
N/A |
3 |
Cat |
Clinical reactivity quantified with inhaled allergen challenge
to cat |
17** |
38.1(15.6) |
52.9% |
N/A |
6* |
49.5 (9.9) |
33.3% |
<0.4 |
4 |
Peanut |
Doctor diagnosed peanut allergy (clinical reactivity
quantified using oral food challenge for 15 subjects, see OLS for
details) |
30* |
24.5 (7.3) |
46.7% |
36.99 (38.60) |
4* |
44.8 (5.1) |
50% |
<0.4 |
5 |
Peanut |
Sensitisation to 1 or more peanut allergen components, but
self-reported ingestion indicating oral tolerance |
13*** |
15.4 (0.9) |
69% |
N/A |
N/A |
N/A |
N/A |
N/A |